Gao Xinxiao, Obeid Anthony, Adam Murtaza K, Hyman Leslie, Ho Allen C, Hsu Jason
Ophthalmic Surg Lasers Imaging Retina. 2019 Mar 1;50(3):159-166. doi: 10.3928/23258160-20190301-05.
To identify the proportion of patients with retinal vein occlusion (RVO) with loss to follow-up (LTFU) along with potential risk factors after receiving an intravitreal anti-vascular endothelial growth factor (VEGF) injection.
A retrospective review based on billing codes was performed from January 1, 2012, to January 1, 2017. LTFU was defined as no office visit within 12 months following an intravitreal injection. Potential risk factors for LTFU were screened using univariate analysis for inclusion in a final multivariate logistic regression model.
A total of 3,400 unique patients with RVO with macular edema met the study inclusion criteria. Of these, 863 patients (25.4%) were LTFU. Rates of LTFU varied based on race / ethnicity, age, RVO type, distance from clinic, insurance status, and regional average adjusted gross income. In the multivariate analysis, patients with LTFU were more likely to be black (odds ratio [OR] = 1.37), Hispanic (OR = 2.37), and living more than 20 miles away from clinic (OR = 1.47). Patients who were 65 to 80 years old (OR = 0.71) and those with branch retinal vein occlusion (OR = 0.70) were less likely to be LTFU. Subgroup analysis showed that patients with baseline visual acuity better than 20/50 were also less likely to be LTFU.
Approximately one in four patients did not return for a year or more after receiving an intravitreal injection for RVO. Given the importance of ongoing therapy to prevent vision loss, these "real-world" findings are of significant concern. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:159-166.].
确定接受玻璃体内抗血管内皮生长因子（VEGF）注射后出现失访（LTFU）的视网膜静脉阻塞（RVO）患者比例以及潜在风险因素。
基于计费代码进行回顾性研究，时间跨度为2012年1月1日至2017年1月1日。LTFU定义为玻璃体内注射后12个月内未进行门诊就诊。使用单因素分析筛选LTFU的潜在风险因素，以纳入最终的多因素逻辑回归模型。
共有3400例患有黄斑水肿的RVO患者符合研究纳入标准。其中，863例患者（25.4%）失访。失访率因种族/民族、年龄、RVO类型、距诊所的距离、保险状况和地区平均调整后总收入而异。在多因素分析中，失访患者更可能为黑人（优势比[OR]=1.37）、西班牙裔（OR=2.37），且居住在距诊所20英里以上（OR=1.47）。65至80岁的患者（OR=0.71）和视网膜分支静脉阻塞患者（OR=0.70）失访的可能性较小。亚组分析显示，基线视力优于20/50的患者失访的可能性也较小。
约四分之一的患者在接受RVO玻璃体内注射后一年或更长时间未复诊。鉴于持续治疗对预防视力丧失的重要性，这些“真实世界”的发现令人高度关注。[《眼科手术、激光与影像学杂志》2019年；50:159 - 166。]
